In cancer cells, the nuclear fraction of the SERPINA3 protein can activate the MAPK/ERK 1/2 and PI3κδ pathways by stimulating the NF-κβ signaling pathway and AKT phosphorylation and stopping the transition from the G2 phase to the M phase. Here, NFKB1 is linked to cancer.